ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Stock Information for ABVC BioPharma Inc.
Loading
Please wait while we load your information from QuoteMedia.